Impact of clinical pharmacist's interventions on clinical outcomes in appropriate use of colistin: a prospective pre-post intervention study.

This study aims to evaluate the clinical pharmacist's contribution impact on the appropriate use of colistin. Our study was conducted prospectively in patients in the Internal Diseases Intensive Care Unit of Gazi University Medical Faculty Hospital for eight months. The first four months of the study were with the observation group, while the next four months were with the intervention group. The study determined how the active participation of clinical pharmacists had affected the appropriateness of colistin use. The results showed that the appropriate use of colistin was higher in the intervention group than in the observational group; furthermore, incidence of nephrotoxicity was lower. The difference between both groups was statistically significant (p < 0.001, p < 0.05), respectively. This study showed that the clinical pharmacist's active intervention by following the patients increased the frequency and percentage of the appropriate use of colistin. This decreased the incidence of nephrotoxicity, colistin's most important side effect.

[1]  K. Seme,et al.  European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM -European Society of intensive care Medicine). , 2021, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  Nurfadhlina Musa,et al.  Population Pharmacokinetics of Colistin Methanesulfonate Sodium and Colistin in Critically Ill Patients: A Systematic Review , 2021, Pharmaceuticals.

[3]  Veena P Menon,et al.  Clinical efficacy and pharmacokinetics of CMS and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant gram-negative bacterial infections-A Prospective Observational Study. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[4]  P. Elsamadisi,et al.  Impact of Colistin Dosing on the Incidence of Nephrotoxicity in a Tertiary Care Hospital in Saudi Arabia , 2020, Antibiotics.

[5]  A. Kwa,et al.  Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study , 2020, Antibiotics.

[6]  H. Gerlach,et al.  Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019— results from a systematic review and meta-analysis , 2020, Critical Care.

[7]  V. Pergialiotis,et al.  Efficacy and safety of colistin loading dose: a meta-analysis. , 2020, The Journal of antimicrobial chemotherapy.

[8]  M. Bassetti,et al.  Use of colistin in adult patients: a cross-sectional study. , 2020, Journal of global antimicrobial resistance.

[9]  Y. Doi,et al.  Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019) , 2020, Emerging microbes & infections.

[10]  D. Chinwong,et al.  Efficacy and Safety of High Loading Dose of Colistin in Multidrug-Resistant Acinetobacter baumannii: A Prospective Cohort Study , 2019, Journal of intensive care medicine.

[11]  G. D. da Rocha,et al.  Occurrence of the potent mutagens 2- nitrobenzanthrone and 3-nitrobenzanthrone in fine airborne particles , 2019, Scientific Reports.

[12]  Ş. Köse,et al.  Risk factors for colistin-associated nephrotoxicity and mortality in critically ill patients , 2017, Turkish journal of medical sciences.

[13]  D. Paterson,et al.  Dosing Guidance for Intravenous Colistin in Critically Ill Patients , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  A. Gous,et al.  COLISTIN: adult and paediatric guideline for South Africa, 2016 , 2016 .

[15]  K. Kaye,et al.  Colistin: Understanding and Applying Recent Pharmacokinetic Advances , 2015, Pharmacotherapy.

[16]  Maartens,et al.  Systematic review of the evidence for rational dosing of colistin : research , 2014 .

[17]  Ronald N. Jones,et al.  Polymyxins: wisdom does not always come with age. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  J. Rolain,et al.  Colistin: an update on the antibiotic of the 21st century , 2012, Expert review of anti-infective therapy.

[19]  Xavier Monnet,et al.  Hemodynamic parameters to guide fluid therapy , 2011, Annals of intensive care.

[20]  Matthew E Falagas,et al.  Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  A. Erbay,et al.  Evaluation of risk factors for mortality in intensive care units: a prospective study from a referral hospital in Turkey. , 2005, American journal of infection control.

[22]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[23]  Norbert Lameire,et al.  Notice , 2012, Kidney International Supplements.